Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
Manouchehri N, Salinas VH, Yeganeh N, Pitt D, Hussain RZ, Stuve O. Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Frontiers In Neurology 2022, 13: 854390. PMID: 35432156, PMCID: PMC9009145, DOI: 10.3389/fneur.2022.854390.Peer-Reviewed Original ResearchProgressive multiple sclerosisSecondary progressive MSMultiple sclerosisImmune senescenceSecondary progressive multiple sclerosisDifferent MS phenotypesDisease-Modifying TherapiesSuccessful clinical managementAge-related factorsAdvent of diseaseModifying therapiesProgressive MSRelapse frequencyClinical managementImmune responseDistinct pathogenesesImmune systemM phenotypeDisease transitionTherapyMain correlatesDisease phenotypePatientsRRMSSignal changes